Myosin Therapeutics Secures Funding to Advance Key Therapies
Myosin Therapeutics, Inc., a pioneering biotechnology firm, has successfully completed its second seed funding round with over $3 million raised. This funding aims to support the company’s vital work in developing groundbreaking treatments for cancer and neurological disorders.
Advancements in Glioblastoma Treatment
The company is meticulously advancing its leading compound, MT-125, which specifically targets glioblastoma, an aggressive form of brain cancer known for its grim prognosis and average survival time of about eight months. MT-125 operates by blocking a critical molecular nanomotor, effectively inhibiting the tumor’s growth and capacity to invade healthy brain tissue. This innovative therapy has also received orphan drug designation from the FDA, highlighting its promise in enhancing the lives of those afflicted by malignant gliomas.
Focus on Substance Use Disorders
In addition to cancer therapies, Myosin Therapeutics is making strides with its other compound, MT-110, intended to treat methamphetamine use disorder (MUD). MUD significantly impacts millions globally, yet the options for FDA-approved therapies remain limited. With the newly acquired funding, coupled with support from the National Institutes of Health, MT-110 will soon commence Phase 1 clinical trials, providing hope for a critical treatment gap.
Strategic Partnerships and Investment Support
The recent seed funding round was primarily led by a consortium of dedicated investors, including DeepWork Capital, Florida Opportunity Fund, and Mint12 Pharma, alongside Dynagrow Capital. Notable participation also came from Mayo Clinic Ventures and The Sontag Innovation Fund, which play a pivotal role in advancing innovative solutions in brain cancer treatment. As expressed by Dave Adams from Mint12 Pharma, Myosin Therapeutics showcases remarkable organizational proficiency, consistently achieving key milestones in its development processes.
Commitment to Innovating Patient Care
Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics, remarked on the significance of the funding, stating, "This funding is pivotal as it will allow us to initiate multiple clinical trials this year, including a Phase 1b trial for MT-125 in glioblastoma patients. We are deeply grateful to our investors for their support as we work to bring innovative therapies to patients with cancer and substance use disorders." This commitment underscores the company's determination to bring forth novel therapies that could drastically change the standard of care.
About Myosin Therapeutics
Myosin Therapeutics is a biotechnology entity based in Jupiter, Florida, emerging from The Herbert Wertheim UF Scripps Institute. The company is focused on advancing therapies targeting neuroscience and oncology through innovative methods that engage molecular nanomotor proteins.
Frequently Asked Questions
What recent funding round did Myosin Therapeutics complete?
Myosin Therapeutics completed a second seed funding round raising over $3 million to enhance its therapeutic developments.
What is MT-125 and its significance?
MT-125 is a lead compound of Myosin Therapeutics aiming to treat glioblastoma, an aggressive brain cancer, which has received orphan drug designation from the FDA.
What other therapies is the company developing?
The company is also focused on MT-110, targeting methamphetamine use disorder, with plans for Phase 1 clinical trials.
Who are the key investors in the funding round?
Key investors include DeepWork Capital, Florida Opportunity Fund, Mint12 Pharma, and Mayo Clinic Ventures among others.
What is the mission of Myosin Therapeutics?
Myosin Therapeutics aims to innovate treatments for cancer and neurological diseases, focusing on impactful and transformative solutions for patients.
